These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 34994647)

  • 1. Budget Impact Analysis of Comprehensive Genomic Profiling in Patients With Advanced Non-Small-Cell Lung Cancer.
    Harvey MJ; Cunningham R; Sawchyn B; Montesion M; Reddy P; McBride A; Chawla AJ
    JCO Precis Oncol; 2021 Nov; 5():1611-1624. PubMed ID: 34994647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use.
    Proudman D; DeVito NC; Belinson S; Allo MA; Morris ED; Signorovitch J; Patel AK
    J Med Econ; 2022; 25(1):817-825. PubMed ID: 35593483
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and Budget Impact of Liquid-Biopsy-Based Comprehensive Genomic Profile (CGP) Testing in Tissue-Limited Advanced Non-Small Cell Lung Cancer (aNSCLC) Patients.
    Patel YP; Husereau D; Leighl NB; Melosky B; Nam J
    Curr Oncol; 2021 Dec; 28(6):5278-5294. PubMed ID: 34940080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
    Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
    JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world clinical and economic outcomes for patients with advanced non-small cell lung cancer enrolled in a clinical trial following comprehensive genomic profiling via liquid biopsy.
    Wiedower JA; Forbes SP; Tsai LJ; Liao J; Raez LE
    J Manag Care Spec Pharm; 2024 Jul; 30(7):660-671. PubMed ID: 38950156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
    Tsai YL; Chang CJ
    Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget Impact of Next-Generation Sequencing for Molecular Assessment of Advanced Non-Small Cell Lung Cancer.
    Yu TM; Morrison C; Gold EJ; Tradonsky A; Arnold RJG
    Value Health; 2018 Nov; 21(11):1278-1285. PubMed ID: 30442274
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive genomic profiling for non-small-cell lung cancer: health and budget impact.
    Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
    Curr Oncol; 2020 Dec; 27(6):e569-e577. PubMed ID: 33380872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung Cancer.
    Yorio J; Lofgren KT; Lee JK; Tolba K; Oxnard GR; Schrock AB; Huang RSP; Brisbin L
    JCO Precis Oncol; 2024 Mar; 8():e2300292. PubMed ID: 38452312
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted erlotinib for first-line treatment of advanced non-small cell lung cancer: a budget impact analysis.
    Bajaj PS; Veenstra DL; Goertz HP; Carlson JJ
    J Med Econ; 2014 Aug; 17(8):538-46. PubMed ID: 24716717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of large-panel next-generation sequencing in guiding first-line treatment decisions for patients with nonsquamous advanced non-small cell lung cancer.
    Abbass IM; Sheinson DM; Shah A; Gondos A; Ogale S
    J Manag Care Spec Pharm; 2024 Jul; 30(7):649-659. PubMed ID: 38950160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.
    Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF
    Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.
    Matsuda H; Ogawa T; Sadatsuki Y; Tsujino T; Wada S; Kim SW; Hatanaka Y
    Respir Investig; 2023 Jan; 61(1):61-73. PubMed ID: 36460584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Budget impact of erlotinib for maintenance therapy in advanced non-small cell lung cancer.
    Carlson JJ; Wong WB; Veenstra DL; Reyes C
    J Med Econ; 2011; 14(2):159-66. PubMed ID: 21288059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Financial Implications of Avapritinib for Treatment of Unresectable Gastrointestinal Stromal Tumors in Patients With a PDGFRA Exon 18 Variant or After 3 Previous Therapies in a Hypothetical US Health Plan.
    Proudman D; Miller A; Nellesen D; Gomes A; Mankoski R; Norregaard C; Sullivan E
    JAMA Netw Open; 2020 Nov; 3(11):e2025866. PubMed ID: 33201235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost Effectiveness of Multigene Panel Sequencing for Patients With Advanced Non-Small-Cell Lung Cancer.
    Steuten L; Goulart B; Meropol NJ; Pritchard D; Ramsey SD
    JCO Clin Cancer Inform; 2019 Jun; 3():1-10. PubMed ID: 31242043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Costs of in-house genomic profiling and implications for economic evaluation: a case example of non-small cell lung cancer (NSCLC).
    Johnston KM; Sheffield BS; Yip S; Lakzadeh P; Qian C; Nam J
    J Med Econ; 2020 Oct; 23(10):1123-1129. PubMed ID: 32597288
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.